Skip to main content
. 2022 Jul 22;199(5):665–678. doi: 10.1111/bjh.18370

TABLE 3.

Outcomes to TKI in combination with AML chemotherapy in myeloid BP‐CML

Combination Reference(s) No. of patients CHR (%) CCyR (%) alloHSCT (%) Median OS (mo)
Ponatinib + FLAG‐IDA 10 17 (incl. 4 lBP) 19 50 70.6 12
Dasatinib + FLAG‐IDA 98 4 (incl 1 lBP) 100 75 100 N/A
Imatinib + ‘7+3’ daunorubicin/cytarabine 99 36 56 30.6 30.6 16
Imatinib + idarubicin/idarubicin + cytarabine 100 19 47 15.8 26.3 5
Imatinib + mitoxantrone/etoposide 101 16 81 N/A 37.5 6.4
Imatinib + decitabine 53 10 20 10 N/A 3.5
Dasatinib + decitabine 54 30 (incl AP n = 7 and Ph+AML n = 4) 48 33.3 26.7 13.8
Dasatinib or nilotinib or ponatinib + azacytidine 55 7 71 43 N/A 27.4
Imatinib + omacetaxine 102 12 58 27.3 72.7 N/A; 75% OS at 12 months

Abbreviations: alloHSCT, allogeneic haemopoietic stem cell transplantation; AP, accelerated phase; CCyR, complete cytogenetic remission; CHR, complete haematologic remission; FLAG‐IDA, fludarabine, cytarabine, granulocyte‐colony stimulating factor, idarubicin; lBP, lymphoid blast phase; N/A, data not available; OS, overall survival; Ph+AML, Philadelphia chromosome‐positive acute myeloid leukaemia.